Webinar: An interesting new study at NCI: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Biliary Tract Carcinoma

Webinar: An interesting new study at NCI: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Biliary Tract Carcinoma